Nine-valent human papillomavirus vaccine shows favourable safety profile
Safety data of the 9-valent human papillomavirus vaccine (9vHPV) from the Vaccine Adverse Event Reporting System (VAERS) during the first 3 years of its licensure in the United States have shown neither new or unexpected safety signals, nor unusual reporting patterns for clinically important adverse events (AEs), as reported in a study. Furthermore, the safety profile of the vaccine is similar to that of its quadrivalent predecessor (4vHPV).